Decreases survival in hormone receptor-positive cell lines MCF-7 and T47D with low nanomolar potency.Destabilizes estrogen receptor (ER) and progesterone receptor (PR) in a dose-dependent manner.Shows strong anticancer activity in vivo by inhibiting expression and survival of ER/PR proteins in hormone receptor-positive cells.Prevents triple-negative breast cancer (TNBC) cells from expressing oncogenic signals and growing tumors.Proves highly cytotoxic to the inflammatory breast cancer (IBC) cell line SUM149. This evidence concerns the gene PGR and triple-negative breast carcinoma.